ArticleMedical microbiology and immunology2018
Anti-Candida activity of antidepressants sertraline and fluoxetine: effect upon pre-formed biofilms.
Article in Medical microbiology and immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Weight Gain During SSRI Therapy: The Potential Role of the Gut Microbiota-A Narrative Review and Mechanistic Hypothesis.Nutrients · 2026Review
- Therapeutic Repurposing of Sertraline: Evidence for Its Antifungal Activity from In Vitro, In Vivo, and Clinical Studies.Microorganisms · 2025Review
- Co-Treatment with Ritonavir or Sertraline Enhances Itraconazole Efficacy Against Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Article
- Serotonin-modulating therapies for the management of chronic wounds.Frontiers in pharmacology · 2025Review
- Exploring the Antibiofilm Effect of Sertraline in Synergy withPharmaceuticals (Basel, Switzerland) · 2024Article
- Mechanistic insights into antifungal potential of Alexidine dihydrochloride and hexachlorophene in Candida albicans: a drug repurposing approach.Archives of microbiology · 2024Article
- In vitro effects of selective serotonin reuptake inhibitors on Cryptococcus gattii capsule and biofilm.Pathogens and disease · 2024Article
- Repurposing approved drugs as potential efflux pump inhibitors in multidrug-resistantFuture microbiology · 2024Article
- Anti-Candidal Activity of Reboxetine and Sertraline Antidepressants: Effects on Pre-Formed Biofilms.Antibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Activity of Sertraline onInternational journal of molecular sciences · 2023Article
- Review
- The potential action of SSRIs in the treatment of skin diseases including atopic dermatitis and slow-healing wounds.Pharmacological reports : PR · 2022Review
- Virulence Factors as Promoters of Chronic Vulvovaginal Candidosis: A Review.Mycopathologia · 2021Review
- Drug repurposing strategies in the development of potential antifungal agents.Applied microbiology and biotechnology · 2021Review
- In Vitro Confirmation of Siramesine as a Novel Antifungal Agent with In Silico Lead Proposals of Structurally Related Antifungals.Molecules (Basel, Switzerland) · 2021Article
- A recombinant fungal defensin-like peptide-P2 combats Streptococcus dysgalactiae and biofilms.Applied microbiology and biotechnology · 2021Article
- Antifungal and Antibiofilm Activities of Selective Serotonin Reuptake Inhibitors Alone and in Combination with Fluconazole.Turkish journal of pharmaceutical sciences · 2020Article
- Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2020Review
- Candida Biofilms: An Update on Developmental Mechanisms and Therapeutic Challenges.Mycopathologia · 2020Review
- Nine Things Genomics Can Tell Us AboutFrontiers in genetics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
As an opportunistic fungal pathogen Candida spp. has the ability to form biofilms. The most prescribed drugs for Candida infections, azoles, have shown to be less effective when biofilms are present. In addition, increasing treatment costs and the fact that most prescribed antifungal drugs have only fungistatic activity justify the search for new treatment strategies. One promising approach is third generation antidepressants, selective serotonin re-uptake inhibitors (SSRIs), because of their proven antifungal activity against several Candida spp. Thus, the aim of this work was to determine the ability of two commonly used SSRIs, fluoxetine and sertraline, to impair both biofilm metabolic viability and biofilm biomass. The in vitro effect of fluoxetine and sertraline was individually tested against biofilm metabolic viability and biofilm biomass using the MTT assay and the Crystal Violet assay, respectively. For both drugs, a dose-dependent reduction on both biofilm metabolism and biomass was present. At high concentrations, fluoxetine was able to reduce biofilm metabolism by 96% (C. krusei) and biofilm biomass by 82% (C. glabrata), when compared to the control. At similar conditions, sertraline achieved a reduction of 88% on biofilm biomass (C. glabrata) and 90% on biofilm metabolism (C. parapsilosis). Moreover, fluoxetine showed interesting anti-biofilm activity at previously reported planktonic MIC values and even at sub-MIC values. These results reinforce the potential interest of SSRIs as anti-biofilm agents to be study to counteract resistance phenomena on candidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.